CSS
ACRS icon

Cubist Systematic Strategies’s Aclaris Therapeutics ACRS Stock Holding History

Cubist Systematic Strategies’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-86,348
Closed -$132K – 2907
2025
Q1 		$132K Sell
86,348
-169,744
-66% -$362K ﹤0.01% 2598
2024
Q4 		$635K Buy
256,092
+249,121
+3,574% +$620K ﹤0.01% 2058
2024
Q3 		$8.02K Sell
6,971
-37,812
-84% -$46.4K ﹤0.01% 2855
2024
Q2 		$49.3K Sell
44,783
-119
-0.3% -$140 ﹤0.01% 2709
2024
Q1 		$55.7K Sell
44,902
-90,393
-67% -$108K ﹤0.01% 3363
2023
Q4 		$142K Buy
135,295
+92,271
+214% +$282K ﹤0.01% 3099
2023
Q3 		$295K Sell
43,024
-15,897
-27% -$136K ﹤0.01% 2607
2023
Q2 		$611K Buy
58,921
+3,946
+7% +$35.7K ﹤0.01% 2269
2023
Q1 		$445K Buy
+54,975
New +$698K ﹤0.01% 2740
2022
Q4 		– Sell
-8,109
Closed -$128K – 4192
2022
Q3 		$128K Sell
8,109
-941
-10% -$14.8K ﹤0.01% 3933
2022
Q2 		$126K Buy
9,050
+5,621
+164% +$78.8K ﹤0.01% 3885
2022
Q1 		$59K Sell
3,429
-17,583
-84% -$240K ﹤0.01% 3348
2021
Q4 		$306K Buy
21,012
+2,012
+11% +$30.5K ﹤0.01% 2782
2021
Q3 		$342K Sell
19,000
-34,257
-64% -$549K ﹤0.01% 2278
2021
Q2 		$935K Sell
53,257
-10,945
-17% -$249K 0.01% 1621
2021
Q1 		$1.62M Buy
+64,202
New +$1.26M 0.02% 1190
2019
Q4 		– Sell
-10,533
Closed -$11K – 2389
2019
Q3 		$11K Sell
10,533
-500
-5% -$709 ﹤0.01% 2142
2019
Q2 		$24K Sell
11,033
-10,115
-48% -$55.1K ﹤0.01% 2377
2019
Q1 		$127K Sell
21,148
-64,914
-75% -$430K ﹤0.01% 1941
2018
Q4 		$636K Buy
+86,062
New +$887K 0.03% 808
2018
Q2 		– Sell
-8,361
Closed -$146K – 1757
2018
Q1 		$146K Buy
8,361
+7,009
+518% +$149K 0.01% 1508
2017
Q4 		$33K Sell
1,352
-4,165
-75% -$101K ﹤0.01% 1809
2017
Q3 		$142K Buy
+5,517
New +$148K 0.01% 1551

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Cubist Systematic Strategies's ACRS Position: Q2 2025 in Review

Cubist Systematic Strategies sold out of Aclaris Therapeutics (ACRS) in Q2 2025, closing a stake of 86,348 shares — an estimated $132K sold.

Cubist Systematic Strategies first reported a position in ACRS in Q3 2017 and held it in 23 quarters. The position peaked at $1.62M in Q1 2021. 96 funds tracked by Wall St. Rank hold ACRS as of Q2 2025.

  • Cubist Systematic Strategies reported no remaining Aclaris Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Cubist Systematic Strategies sold 86,348 Aclaris Therapeutics shares in Q2 2025, an estimated $132K.
  • Cubist Systematic Strategies first reported a position in Aclaris Therapeutics in Q3 2017 and held it in 23 quarters.
  • Cubist Systematic Strategies's Aclaris Therapeutics position peaked at $1.62M in Q1 2021.
  • 96 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2025.

Based on Cubist Systematic Strategies's 13F filing for Q2 2025, filed 14 Aug 2025.